---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-034103"
form_type: "8-K"
ticker: "QUCY"
cik: "0001874252"
company_name: "Quantum Cyber N.V."
filed_at: "2026-03-25T23:59:59+00:00"
generated_at: "2026-05-15T09:04:29.273635+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Mainz Biomed receives Nasdaq minimum bid price deficiency notice; 180-day cure period until Sep 16, 2026

## Summary
- Nasdaq notified Mainz Biomed on Mar 20, 2026 that its share price closed below $1.00 for 30 consecutive business days through Mar 19, 2026.
- Company has 180 calendar days, until Sep 16, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days.
- If not cured by Sep 16, 2026, Mainz may be eligible for an additional 180-day period if it meets other listing standards and notifies Nasdaq of intent to cure via reverse stock split.
- There can be no assurance of regaining compliance or avoiding delisting; the letter has no immediate impact on trading.

## SEC filing metadata
- accession: 0001213900-26-034103
- form_type: 8-K
- ticker: QUCY
- cik: 0001874252
- company_name: Quantum Cyber N.V.
- filed_at: 2026-03-25T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1874252/000121390026034103/0001213900-26-034103-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1874252/000121390026034103/ea0283153-8k_mainz.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-034103
- JSON: https://secwatch.observer/filing/0001213900-26-034103.json
- Plain text: https://secwatch.observer/filing/0001213900-26-034103.txt

## Key facts
- Listing & Compliance Notices
  Quantum Cyber N.V. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5810(c)(3)(A)
  source text: March 20, 2026, Mainz Biomed N.V. (the “ Company ”) received a letter from the Listing Qualifications Department of the Nasdaq Stock Market indicating that, based upon the closing bid price of the Company’s ordinary shares, nominal value €0.01 per share (the “ Ordinary Shares ”) for the 30 consecutive business days between February 5, 2026, to March 19, 2026, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market (“ Nasdaq ”) pursuant to Nasdaq Listing Rule 5550(a)(2). The letter also indicated that the Company will be prov
  evidence_url: https://www.sec.gov/Archives/edgar/data/1874252/000121390026034103/0001213900-26-034103-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.